NCT07390851 Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
| NCT ID | NCT07390851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Myofascial Pain Dysfunction Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2025-11-26 |
| Primary Completion | 2026-11-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 28 participants in total. It began in 2025-11-26 with a primary completion date of 2026-11-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 70 years. 2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS). 3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius). 4. Pain duration ≥ 3 months. 5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS). 6. Noprior trigger point injection in the affected area within the past 3 months. 7. Ability and willingness to provide informed consent. 8. Compliance with study visits and procedures Exclusion Criteria: 1. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents. 2. Current use of anticoagulants or history of bleeding disorders. 3. Systemic or local infection at or near the injection site. 4. History of fibromyalgia, central pain syndromes, or cancer-related pain. 5. Major psychiatric illnesses (e.g., schizophrenia, severe depression). 6. Recent surgery or trauma to the head, neck, or upper back (\<6 months). 7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention. 8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.
Contact & Investigator
Maii E Abdelazeem, Bsc
PRINCIPAL INVESTIGATOR
Faculty of Oral & Dental Medicine, Cairo University
Frequently Asked Questions
Who can join the NCT07390851 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Myofascial Pain Dysfunction Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07390851 currently recruiting?
Yes, NCT07390851 is actively recruiting participants. Contact the research team at Maii.emad@dentistry.cu.edu.eg for enrollment information.
Where is the NCT07390851 trial being conducted?
This trial is being conducted at Giza, Egypt.
Who is sponsoring the NCT07390851 clinical trial?
NCT07390851 is sponsored by Cairo University. The principal investigator is Maii E Abdelazeem, Bsc at Faculty of Oral & Dental Medicine, Cairo University. The trial plans to enroll 28 participants.